← back to search

Kevin Brown

Animal and Plant Health Agency · US
Area of research
Infectious Diseases · Dermatology
Research interest
Research interests include Parvovirus B19 Infection Studies, SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, and Dermatological and COVID-19 studies.
h-index
75
citations
24,978
works
416
NIH funding
primary concept
Medicine
email

Recent publications

Seroprevalence of measles antibodies in children with cancer: results of a 2024 UK service evaluation.
2026cited by 0position: contributordoi
Tick-borne encephalitis: from tick surveillance to the first confirmed human cases, the United Kingdom, 2015 to 2023
Eurosurveillance 2025cited by 13position: middledoi
Understanding mechanisms of thrombosis and thrombocytopenia with adenoviral SARS-CoV-2 vaccines: a comprehensive synopsis
Efficacy and Mechanism Evaluation 2025cited by 2position: contributordoi
Understanding mechanisms of thrombosis and thrombocytopenia with adenoviral SARS-CoV-2 vaccines: a comprehensive synopsis
2025cited by 0position: contributor
The impact of vaccination and SARS-CoV-2 variants on the virological response to SARS-CoV-2 infections during the Alpha, Delta, and Omicron waves in England
Journal of Infection 2024cited by 17position: contributordoi
COVID-19 reinfection in pregnancy: Assessment of severity and pregnancy outcomes in England
Journal of Infection 2024cited by 3position: middledoi
Paediatric acute hepatitis of unknown aetiology: a national investigation and adenoviraemia case-control study in the UK
The Lancet Child & Adolescent Health 2023cited by 24position: middledoi
The impact of vaccination and SARS-CoV-2 variants on the virological response to SARS-CoV-2 infections during the Alpha, Delta, and Omicron waves in England
Journal of Infection 2023cited by 16position: middledoi
Following the Omicron wave, the majority of children in England have evidence of previous COVID infection.
2023cited by 14position: contributordoi
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
2022cited by 1,861position: contributordoi
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
2022cited by 552position: contributordoi
Extended interval BNT162b2 vaccination enhances peak antibody generation.
2022cited by 134position: contributordoi
Disease severity during SARS-COV-2 reinfection: a nationwide study
Journal of Infection 2022cited by 71position: contributordoi
Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2.
2022cited by 69position: contributordoi
VITT and Second Doses of Covid-19 Vaccine.
2022cited by 37position: contributordoi
Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.
2022cited by 18position: contributordoi
Epidemiology of SARS-CoV-2 infection among staff and students in a cohort of English primary and secondary schools during 2020–2021
The Lancet Regional Health - Europe 2022cited by 11position: middledoi
Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network.
2022cited by 10position: contributordoi
Secondary attack rates in primary and secondary school bubbles following a confirmed case: Active, prospective national surveillance, November to December 2020, England
PLoS ONE 2022cited by 6position: middledoi
Effectiveness of oral aciclovir in preventing maternal chickenpox: A comparison with VZIG.
2022cited by 4position: contributordoi
Author Correction: Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England.
2022cited by 1position: contributordoi
Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5
2022cited by 1position: contributordoi
Serological responses and six-month trajectories to COVID-19 Comirnaty and Spikevax booster vaccine, September 2021 to January 2022, London, United Kingdom
2022cited by 1position: contributordoi
Effectiveness of oral aciclovir in preventing maternal chickenpox: A comparison with VZIG
2022cited by 0position: contributordoi
Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England
2022cited by 0position: contributordoi
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
2021cited by 2,165position: contributordoi
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
BMJ 2021cited by 1,395position: middledoi
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England.
2021cited by 96position: contributordoi
SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study.
2021cited by 76position: contributordoi
Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
Eurosurveillance 2021cited by 66position: middledoi

Grants

HSI Planning Project: Examining Inclusion and Other Variables of STEM Retention at a Faith-Based, Residential University
NSF2345328$195,2162024–2026PIRePORTER
CRCNS US-Spain Research Proposal: Collaborative Research: Tracking and modeling the neurobiology of multilingual speech recognition
NSF2207747$186,4792022–2026PIRePORTER
Collaborative Research: CompCog: Psychological, Computational, and Neural Adequacy in a Deep Learning Model of Human Speech Recognition
NSF2043950$178,9342021–2026PIRePORTER
Collaborative Research: Modeling Spatiotemporal Control of EGFR-ERK Signaling in Gene-edited Cell Systems
NSF1906161$150,0102018–2022PIRePORTER
Collaborative Research: Modeling Spatiotemporal Control of EGFR-ERK Signaling in Gene-edited Cell Systems
NSF1715342$164,7172017–2019PIRePORTER
DCL: NSF INCLUDES Conference - Collaborative Research: Envisioning Impact
NSF1650289$152,4202016–2017PIRePORTER
Experimental and theoretical investigation of rock friction at seismic slip rates
NSF0838255$225,4262009–2012PIRePORTER
A Moored Geodetic Seafloor Monitoring System (GEOCE)
NSF0551363$1,314,2552007–2011PIRePORTER
Hydrologic Monitoring at the Nantroseize OOST Zone: A Pilot Study
NSF0646811$145,9162007–2009PIRePORTER
SGER - Hydrologic Monitoring of Leaking Coseismically Active Thrusts: A Pilot Study in the Nankai Subduction Zone
NSF0628676$52,0892006–2007PIRePORTER
Next Generation Flux Meters For Enhanced Geochemical And High-Resolution Real-Time Benthic Flux Monitoring
NSF0241998$236,7042003–2007PIRePORTER
Collaborative Research: Frictional and Mineralogical Properties of Sediments Entering Subduction Zones: Controls on Stress State and Earthquakes
NSF0203799$150,4562002–2005PIRePORTER
Hydrologic Controls on the Initial State of the Incoming Plate: Costa Rica
NSF0203830$113,0952002–2004PIRePORTER
Collaborative Research: Physical and Chemical Constraints on Fluxes at LExEn Gas Hydrate Sites in the Gulf of Mexico
NSF0118101$123,3992001–2003PIRePORTER
Benthic Flux Meter Study Across the Costa Rica Margin
NSF9907201$64,5641999–2001PIRePORTER
Collaborative Research: Geochemical Consequences of Extensive Gas Hydrate Formuation in Sediments of the Cascadia Accretionary Prism
NSF9731463$186,3081998–2002PIRePORTER
Development of a New Fluid and Geochemical Flux Meter for Seafloor Measurements on Convergent Margins and Ridge Flanks
NSF9633378$384,1421996–1999PIRePORTER
The Coupled Physical and Chemical Processes That Drive Fluid Production and Overpressure Development in Convergent Margins: An Experimental Study
NSF9529959$221,9361996–2001PIRePORTER
Deep Fluid Sources in Accretionary Wedges: A Quantitative Study of Diagenetically Related Fluid Protection and Physical Property Changes in Clay Rich Sediments
NSF9402437$95,0811994–1997PIRePORTER

Frequent collaborators

Shamez Ladhani · Future Earth26 papers (2020–2023) · 21 papers (2021–2026)Jamie Lopez Bernal · Public Health Agency14 papers (2021–2024)Gayatri Amirthalingam · Environment Agency7 papers (2020–2022)Mary Ramsay · National Institute for Health and Care Excellence7 papers (2020–2025)Julia Stowe · BC Centre for Disease Control7 papers (2021–2024)Paul Moss · Imperial College London6 papers (2021–2022) · 6 papers (2020–2022)Heather Whitaker · Imperial College London4 papers (2020–2022)Maria Zambon · Public Health Agency4 papers (2012–2024)Susan Hopkins · United Kingdom Council for Psychotherapy3 papers (2021–2022)Brian J Willett · MRC University of Glasgow Centre for Virus Research3 papers (2021–2022)Helen Campbell · Manchester Metropolitan University3 papers (2022–2022)Ray Borrow · East London NHS Foundation Trust3 papers (2020–2022) · 3 papers (2021–2023) · 3 papers (2022–2023)Jianmin Zuo · Institut thématique Immunologie, inflammation, infectiologie et microbiologie3 papers (2021–2022)Simon de Lusignan · UK Health Security Agency3 papers (2021–2022)Alex Horsley · MRC University of Glasgow Centre for Virus Research3 papers (2020–2021)Shamez Ladhani · Future Earth3 papers (2020–2024)